| Literature DB >> 21269928 |
Mark J Mendell1, Anna G Mirer, Kerry Cheung, My Tong, Jeroen Douwes.
Abstract
OBJECTIVES: Many studies have shown consistent associations between evident indoor dampness or mold and respiratory or allergic health effects, but causal links remain unclear. Findings on measured microbiologic factors have received little review. We conducted an updated, comprehensive review on these topics. DATA SOURCES: We reviewed eligible peer-reviewed epidemiologic studies or quantitative meta-analyses, up to late 2009, on dampness, mold, or other microbiologic agents and respiratory or allergic effects. DATA EXTRACTION: We evaluated evidence for causation or association between qualitative/subjective assessments of dampness or mold (considered together) and specific health outcomes. We separately considered evidence for associations between specific quantitative measurements of microbiologic factors and each health outcome. DATA SYNTHESIS: Evidence from epidemiologic studies and meta-analyses showed indoor dampness or mold to be associated consistently with increased asthma development and exacerbation, current and ever diagnosis of asthma, dyspnea, wheeze, cough, respiratory infections, bronchitis, allergic rhinitis, eczema, and upper respiratory tract symptoms. Associations were found in allergic and nonallergic individuals. Evidence strongly suggested causation of asthma exacerbation in children. Suggestive evidence was available for only a few specific measured microbiologic factors and was in part equivocal, suggesting both adverse and protective associations with health.Entities:
Mesh:
Year: 2011 PMID: 21269928 PMCID: PMC3114807 DOI: 10.1289/ehp.1002410
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Total numbers of published studies on health effects: those cited by the IOM review (IOM 2004) and those identified later and included in this review, plus summarya of findings only for qualitativeb assessments of dampness or mold.
| Total number of studies
| Summary of qualitative assessments of dampness or mold | ||||
|---|---|---|---|---|---|
| Health outcome category | Study design | IOM review | New | OR range | Proportion of total estimates showing any positive association with D/M |
| Asthma development | Prospective | 2 | 4 | 0.65–7.08 | 7/9 |
| Retrospective | 6 | 2 | 0.63–4.12 | 29/38 | |
| Cross-sectional | 0 | 3 | 1.6–2.2 | 2/2 | |
| Asthma symptoms in asthmatic people (exacerbation) | Intervention | 0 | 3 | No ORs | 22/22 |
| Prospective | 0 | 1 | 3.8–7.6 | 2/2 | |
| Retrospective | 5 | 0 | 1.5–4.9 | 7/7 | |
| Cross-sectional | 18 | 4 | 1.0–7.6 | 45/47 | |
| Ever-diagnosed asthma | Prospective | — | 2 | 1.2–1.3 | 2/2 |
| Cross-sectional | — | 18 | 0.6–2.6 | 31/33 | |
| Current asthma | Prospective | — | 1 | No qual | No qual |
| Cross-sectional | — | 25 | 0.3–13.0 | 60/64 | |
| Dyspnea | Intervention | 0 | 1 | No ORs | 2/2 |
| Cross-sectional | 4 | 11 | 0.4–9.4 | 56/67 | |
| Wheeze | Intervention | 0 | 1 | No ORs | 7/8 |
| Prospective | 0 | 12 | 0.68–6.17 | 35/37 | |
| Retrospective | 1 | 1 | 1.5–2.8 | 9/9 | |
| Cross-sectional | 19 | 41 | 0.44–8.67 | 151/164 | |
| Bronchitis | Prospective | — | 1 | 0.7–3.8 | 4/5 |
| Cross-sectional | — | 11 | 1.2–2.4 | 19/19 | |
| Altered lung function | Intervention | — | 2 | No ORs | 6/6 |
| Prospective | — | 2 | No ORs | 7/13 | |
| Retrospective | — | 1 | No ORs | 4/8 | |
| Cross-sectional | — | 6 | No ORs | 8/9 | |
| Cough | Prospective | 0 | 2 | 0.54–2.14 | 7/9 |
| Retrospective | 1 | 0 | 1.18–1.90 | 4/4 | |
| Cross-sectional | 20 | 26 | 0.21–5.74 | 140/147 | |
| Respiratory infections and otitis media | Prospective | — | 5 | 0.45–5.1 | 14/24 |
| Cross-sectional | — | 13 | 0.48–3.14 | 30/37 | |
| Common cold | Prospective | — | 1 | 0.6–1.8 | 4/9 |
| Cross-sectional | — | 5 | 0.98–1.7 | 13/14 | |
| Eczema | Prospective | — | 2 | 1.2–2.9 | 3/3 |
| Cross-sectional | — | 4 | 0.3–1.9 | 13/15 | |
| Allergy/atopy (excluding allergic rhinitis and eczema) | Prospective | — | 7 | 0.6–2.4 | 9/12 |
| Cross-sectional | — | 15 | 1.1–1.9 | 15/19 | |
| Allergic rhinitis | Prospective | — | 2 | 1.2–3.2 | 5/5 |
| Cross-sectional | — | 3 | 0.7–3.5 | 7/8 | |
| Upper respiratory tract symptoms (including allergic rhinitis) | Intervention | 0 | 1 | No ORs | 5/6 |
| Prospective | 0 | 5 | 1.03–3.2 | 11/11 | |
| Retrospective | 0 | 1 | 1.0–1.3 | 1/2 | |
| Cross-sectional | 14 | 20 | 0.37–5.92 | 107/122 | |
| Other respiratory | Prospective | — | 5 | 1.03–1.06 | 4/4 |
| Cross-sectional | — | 13 | 0.45–2.4 | 11/14 | |
| Total studies | 45 | 103 | |||
Abbreviations: —, outcome not included in review; D/M, dampness or mold; no qual, no qualitative exposure assessments in article.
For details regarding the studies in this table, see Supplemental Material, Tables A1.1–A1.6 and A2.1–A2.6 (doi:10.1289/ehp.1002410).
Findings for quantified microbiologic factors omitted.
Includes all reported ratio estimates of effect: ORs, RRs, IRRs.
Proportion of findings with ORs, RRs, or IRRS > 1.0 (or < 1.0 for removal of D/M) or nonratio estimates, such as linear coefficients, greater/less than 0 or 1 as appropriate.
Although all reported ORs/RRs/IRRs exceeded 1.0, other types of estimates were not consistent.
Totals are less than the sum of the numbers above, as each study may report multiple findings.
Summary estimates from three meta-analyses on residential D/M and health.
| Subject groups | OR (95% CI)
| |||
|---|---|---|---|---|
| Upper respiratory tract symptoms | All | 1.70 (1.44–2.00) | ||
| Cough | All | 1.67 (1.49–1.86) | ||
| Adults | 1.52 (1.18–1.96) | 1.30 (1.22–1.39) | ||
| Children | 1.75 (1.56–1.96) | 1.50 (1.31–1.73) | ||
| Wheeze | All | 1.50 (1.38–1.64) | ||
| Adults | 1.39 (1.04–1.85) | 1.43 (1.36–1.49) | ||
| Children | 1.53 (1.39–1.68) | 1.49 (1.28–1.74) | ||
| Current asthma | All | 1.56 (1.30–1.86) | ||
| Ever-diagnosed asthma | All | 1.37 (1.23–1.53) | ||
| Children | 1.35 (1.20–1.51) | |||
| Asthma development | All | 1.34 (0.86–2.10) | ||
| Bronchitis | All | 1.45 (1.32–1.59) | ||
| Children | 1.38 (1.28–1.47) | |||
| Respiratory infections | All | 1.44 (1.31–1.59) | ||
| Adults | 1.49 (1.14–1.95) | |||
| Children | 1.48 (1.33–1.65) | |||
| Respiratory infections | All | 1.50 (1.32–1.70) | ||
| Sensitivity to inhaled antigens | Children | 1.33 (1.23–1.44) | ||
| Hay fever | Children | 1.35 (1.18–1.53) | ||
Based on all eligible published studies at the time, ranging from 4 to 22 studies for each outcome; all risk factors of visible mold, visible water damage, mold odor, and various combinations of these were included together.
Based on a total of 12 studies in 12 countries, including over 57,000 children: 10 studies of any visible mold, 1 study of any visible mold in last 12 months, and 1 study of any visible mold in child’s bedroom.
Nocturnal dry cough.
Morning cough.
Wheeze in the last 12 months.
Woken by wheeze.
Including lower respiratory infections, tonsillitis, sinusitis, otitis, and pharyngitis, but excluding nonspecific upper respiratory infections.
Level of confidence for associations between indoor dampness or dampness-related agentsa and health outcomes, based on epidemiologic evidence.b
| Updated conclusion | Outcome | Additional evidence | Prior IOM conclusion |
|---|---|---|---|
| Sufficient evidence of a causal relationship | (None) | (None) | (None) |
| Sufficient evidence of association | Asthma exacerbation | More studies of strong design (strongly suggestive of causation) | Sufficient evidence of association |
| Cough | Many new studies, some of strong design | Sufficient evidence of association | |
| Wheeze | Many new studies, many of strong design | Sufficient evidence of association | |
| Upper respirator | Many new studies, some of strong design | Sufficient evidence of association | |
| Asthma development | More studies of strong design | Limited or suggestive evidence of association | |
| Dyspnea | More studies | Limited or suggestive evidence of association | |
| Current asthma | Initial evaluation | Not evaluated | |
| Ever-diagnosed asthma | Initial evaluation | Not evaluated | |
| Respiratory infections | Initial evaluation | Not evaluated | |
| Bronchitis | Initial evaluation | Not evaluated | |
| Allergic rhinitis | Initial evaluation | Not evaluated | |
| Eczema | Initial evaluation | Not evaluated | |
| Limited or suggestive evidence of association | Common cold | Initial evaluation | Not evaluated |
| Allergy/atopy | Initial evaluation | Not evaluated | |
| Inadequate or insufficient evidence to determine whether an association exists | Altered lung function | Initial evaluation | Not evaluated |
| Hypersensitivity pneumonitis | (None) | (Association based on clinical evidence) |
Based on evidence of visible water damage, visible mold, mold odor, or similar related factors.
Association between hypersensitivity pneumonitis in susceptible individuals and the presence of mold or other agents is documented by clinical evidence (IOM 2004).
Studies of stronger design include experimental, cohort, or case–control designs.
Statistically significant elevation of risk identified in a quantitative meta-analysis.
Conclusion changed from IOM conclusion.
Measured indoor microbiologic factors with suggestive positive or negative associationsa with specific respiratory or allergic health effects in building occupants.b
| Measured microbiologic factors | Specific health outcomes | Findings with suggestive positive associations | Findings with suggestive negative associations | No. of studies | Range of ORs | References |
|---|---|---|---|---|---|---|
| Ergosterol in dust, higher levels | Current asthma | 5 of 6 (83%) | 3 | 0.92–4-fold | ||
| Endotoxin in dust, higher levels | Wheeze | 20 of 25 (80%) | 14 | 0.67–2.8 | ||
| (1→3)-β- | Wheeze | 7 of 8 (88%) | 3 | 0.89–6.05 | ||
| (1→3)-β- | Wheeze | 10 of 11 (91%) | 4 | 0–1.25 |
A suggestive association required, among reported findings on associations between a specific measured indoor microbiologic factor and a specific respiratory or allergic health outcome, at least 80% consistency of estimates either ≤ 1.0 or > 1.0, among at least five estimates available from three or more studies. This assessment did not consider magnitude of effects, precision, statistical significance, study design, or age of subjects.
Measured microbiologic factors with inadequate or insufficient evidence to determine whether an association exists with any specific health outcome are listed in Supplemental Material, Table A3.1 (doi:10.1289/ehp.1002410).